These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

872 related articles for article (PubMed ID: 30964529)

  • 1. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
    Singal G; Miller PG; Agarwala V; Li G; Kaushik G; Backenroth D; Gossai A; Frampton GM; Torres AZ; Lehnert EM; Bourque D; O'Connell C; Bowser B; Caron T; Baydur E; Seidl-Rathkopf K; Ivanov I; Alpha-Cobb G; Guria A; He J; Frank S; Nunnally AC; Bailey M; Jaskiw A; Feuchtbaum D; Nussbaum N; Abernethy AP; Miller VA
    JAMA; 2019 Apr; 321(14):1391-1399. PubMed ID: 30964529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
    Ricciuti B; Wang X; Alessi JV; Rizvi H; Mahadevan NR; Li YY; Polio A; Lindsay J; Umeton R; Sinha R; Vokes NI; Recondo G; Lamberti G; Lawrence M; Vaz VR; Leonardi GC; Plodkowski AJ; Gupta H; Cherniack AD; Tolstorukov MY; Sharma B; Felt KD; Gainor JF; Ravi A; Getz G; Schalper KA; Henick B; Forde P; Anagnostou V; Jänne PA; Van Allen EM; Nishino M; Sholl LM; Christiani DC; Lin X; Rodig SJ; Hellmann MD; Awad MM
    JAMA Oncol; 2022 Aug; 8(8):1160-1168. PubMed ID: 35708671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
    JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.
    Provencio M; Ortega AL; Coves-Sarto J; Calvo V; Marsé-Fabregat R; Dómine M; Guirado M; Carcereny E; Fernández N; Álvarez R; Blanco R; León-Mateos L; Sánchez-Torres JM; Sullivan IG; Cobo M; Sánchez-Hernández A; Massuti B; Sierra-Rodero B; Mártinez-Toledo C; Serna-Blasco R; Romero A; Cruz-Bermúdez A
    JAMA Oncol; 2023 Mar; 9(3):344-353. PubMed ID: 36520426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting.
    Presley CJ; Tang D; Soulos PR; Chiang AC; Longtine JA; Adelson KB; Herbst RS; Zhu W; Nussbaum NC; Sorg RA; Agarwala V; Abernethy AP; Gross CP
    JAMA; 2018 Aug; 320(5):469-477. PubMed ID: 30088010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
    Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N
    JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab.
    Lebow ES; Shepherd A; Eichholz JE; Offin M; Gelblum DY; Wu AJ; Simone CB; Schoenfeld AJ; Jones DR; Rimner A; Chaft JE; Riaz N; Gomez DR; Shaverdian N
    JAMA Netw Open; 2023 Jan; 6(1):e2249591. PubMed ID: 36602799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
    Barlesi F; Mazieres J; Merlio JP; Debieuvre D; Mosser J; Lena H; Ouafik L; Besse B; Rouquette I; Westeel V; Escande F; Monnet I; Lemoine A; Veillon R; Blons H; Audigier-Valette C; Bringuier PP; Lamy R; Beau-Faller M; Pujol JL; Sabourin JC; Penault-Llorca F; Denis MG; Lantuejoul S; Morin F; Tran Q; Missy P; Langlais A; Milleron B; Cadranel J; Soria JC; Zalcman G;
    Lancet; 2016 Apr; 387(10026):1415-1426. PubMed ID: 26777916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.
    Aggarwal C; Ben-Shachar R; Gao Y; Hyun SW; Rivers Z; Epstein C; Kaneva K; Sangli C; Nimeiri H; Patel J
    JAMA Netw Open; 2023 May; 6(5):e2311181. PubMed ID: 37129893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer.
    Yorio J; Lofgren KT; Lee JK; Tolba K; Oxnard GR; Schrock AB; Huang RSP; Brisbin L
    JCO Precis Oncol; 2024 Mar; 8():e2300292. PubMed ID: 38452312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.
    Willis C; Bauer H; Au TH; Menon J; Unni S; Tran D; Rivers Z; Akerley W; Schabath MB; Badin F; Sekhon A; Patel M; Xia B; Gustafson B; Villano JL; Thomas JM; Lubinga SJ; Cantrell MA; Brixner D; Stenehjem D
    Oncotarget; 2022; 13():257-270. PubMed ID: 35111281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.
    Fang W; Ma Y; Yin JC; Hong S; Zhou H; Wang A; Wang F; Bao H; Wu X; Yang Y; Huang Y; Zhao H; Shao YW; Zhang L
    Clin Cancer Res; 2019 Aug; 25(16):5015-5026. PubMed ID: 31085721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive genomic profiling of Brazilian non-small cell lung cancer patients (GBOT 0118/LACOG0418).
    Mascarenhas E; Gelatti AC; Araújo LH; Baldotto C; Mathias C; Zukin M; Werutsky G; Pacheco P; Gomes R; de Castro G; Cordeiro de Lima VC
    Thorac Cancer; 2021 Mar; 12(5):580-587. PubMed ID: 33314759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer.
    Huang D; Zhang F; Tao H; Zhang S; Ma J; Wang J; Liu Z; Cui P; Chen S; Huang Z; Wu Z; Zhao L; Hu Y
    Target Oncol; 2020 Feb; 15(1):93-100. PubMed ID: 32052340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
    Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
    Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
    Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.